Coverage written from the off-patent industry's point of view rather than as an afterthought to branded pharma reporting.
Exclusive interviews with CEOs and senior leaders across generics, biosimilars and value-added medicines, plus deep ties to industry associations.
Deals, launches, losses of exclusivity, approvals, pricing and litigation in one place, with analysis of what each move means.
The annual ranking of the 50 largest firms across the generics and biosimilars industry, with analysis of how the financial figures stack up year on year.
Generics Bulletin reporters have long-standing relationships with the executives and associations that set the direction of the generics and biosimilars industry.
Generics Bulletin goes beyond reporting the development to explaining what it means for portfolio planning, launch sequencing and competitive positioning.
Acquisitions, licensing agreements, alliances and divestments, with the strategic rationale explained.
Development, approval, interchangeability, naming and uptake across the US, EU and beyond.
Regulatory and policy developments that affect generics and biosimilars specifically.
Patent challenges, litigation, settlements and the exclusivity outcomes that follow.
Pricing pressure, tenders and reimbursement policy across the major off-patent markets.
API supply, CDMO activity, capacity and the shortages that reshape the market.
Heads of portfolio use Generics Bulletin to decide which molecules to pursue, when to enter and where the competition is heading.
BD teams track partnering, in-licensing and acquisition activity across generics, biosimilars and value-added medicines.
IP counsel follow patent challenges, litigation outcomes and settlement terms that determine entry timing.
Supply leaders monitor API sourcing, CDMO capacity and the disruptions that affect continuity of supply.
Regulatory teams track the pathways, guidance and approval decisions that apply specifically to off-patent products.
API suppliers, contract manufacturers and law firms serving the sector use Generics Bulletin to follow their customers' markets.
Norstella’s award-winning publications provide in-depth coverage of the pharmaceutical industry, thanks to 60+ in-house journalists who tackle the tough issues with precision, persistence and passion.
Generics Bulletin’s reporters cover generics, biosimilars and value-added medicines, with combined decades of experience in the off-patent sector and established relationships across the industry and its associations.
